Hi
MindBio Therapeutics (CNSX: MBIO) launches Booze AI to Investors in Silicon Valley.
The World's First Voice Activated & AI Powered Blood Alcohol Estimator over a Smartphone goes Live.
It was a surprising discovery with speech analysis in our clinical trials that led us to developing this novel product. We discovered we could predict whether a patient was taking our drug or not taking our drug, just by analysing their voice. This extraodinary discovery led to intoxication and voice analytics research in parallel with our ongoing two Phase 2B clinical trials.
Download the App and save it to your home screen.
Taking a very broad view to data collection in clinical trials has not only provided a technology platform for precision microdosing, but has also resulted in our first commercialisation opportunity. I'm pleased to announce the release of version 1.0 of Booze AI, the world's first voice activated and AI powered blood alcohol estimator over a smartphone.
Talk into the app on your phone, perform some behavioural tasks and the software is able to predict your blood alcohol concentration and resulting driving performance impairment.
We have discovered in clinical trials, that there is zero amount of alcohol that is safe to drink then drive and the App's main focus is to deter drink driving.
Today, we launched Booze AI to investors in Silicon Valley, a remarkable achievement for our scientists and engineers. Not surprisingly, the App was received positively and has gained a lot of attention and this opens up opportunities for the Company.
Try out the app, download it and save it to your home screen on your phone.
We invite you to join us in support of creating a brighter future for mental health.
Stay Well!
JUSTIN HANKA
Chief Executive Officer & Co-Founder
MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)
0 comments